Mepsevii (Vestronidase Alfa)

Vestronidase alfa is a recombinant form of human beta‑glucuronidase. After intravenous infusion it is taken up by cells via mannose‑6‑phosphate receptors and delivered to lysosomes, where it restores the missing enzymatic activity needed to break down glycosaminoglycans, thereby lowering their pathological storage.

The dose of Mepsevii is individualized by the prescribing clinician based on factors such as the patient’s body weight, disease severity, and response to therapy. Specific dosing regimens are outlined in the product’s prescribing information and should not be altered without medical guidance.

The safety of Mepsevii in pregnant or nursing women has not been fully established. Because the drug is classified as pregnancy category unknown, clinicians should weigh potential benefits against possible risks and discuss these considerations with the patient before initiating therapy.

To request Mepsevii, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Mepsevii is the only approved enzyme replacement therapy specifically targeting the beta‑glucuronidase deficiency in MPS VII. Alternative approaches, such as hematopoietic stem cell transplantation, aim to provide a source of functional enzyme but carry higher procedural risk. Mepsevii offers a targeted, less invasive option that directly replaces the missing enzyme.

Mepsevii must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If temperature excursions occur, the product should be inspected for any visual changes before use.

Mepsevii is supplied as an injectable solution for intravenous infusion. The infusion is performed by a qualified healthcare professional in a clinical setting, following the preparation and administration guidelines outlined in the prescribing information, including appropriate infusion rates and monitoring for reactions.

The most serious adverse events reported with Mepsevii include severe hypersensitivity reactions such as anaphylaxis, significant liver enzyme elevations indicating potential hepatic injury, and hematologic abnormalities like thrombocytopenia. Patients should be monitored closely for these events during and after each infusion.

Mepsevii is contraindicated in individuals with a known severe allergic reaction to vestronidase alfa or any of its excipients. Caution is also advised for patients with a history of severe anaphylaxis to other biologic agents, as they may be at increased risk for hypersensitivity.